Concord Biotech Limited — Results, 13-02-2025: Integrated Filing- Financial

Concord Biotech Limited has announced a board meeting today where the Board of Directors approved the unaudited financial results for the third quarter and nine months ended December 31, 2024. Key highlights include total income of ₹258.95 crore and a profit after tax of ₹74.09 crore. Despite a decline in quarterly revenue compared to previous periods, the company's profitability remains solid. This positive performance could enhance investor sentiment, positioning Concord Biotech as a resilient player in the pharmaceutical sector amidst market fluctuations.